AP2479A - Antibacterial quinoline derivatives - Google Patents

Antibacterial quinoline derivatives

Info

Publication number
AP2479A
AP2479A AP2009004874A AP2009004874A AP2479A AP 2479 A AP2479 A AP 2479A AP 2009004874 A AP2009004874 A AP 2009004874A AP 2009004874 A AP2009004874 A AP 2009004874A AP 2479 A AP2479 A AP 2479A
Authority
AP
ARIPO
Prior art keywords
quinoline derivatives
antibacterial quinoline
antibacterial
derivatives
quinoline
Prior art date
Application number
AP2009004874A
Other languages
English (en)
Other versions
AP2009004874A0 (en
Inventor
Jerome Emile Georges Guillemont
David Francis Alain Laneois
Ismet Dorange
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38126091&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AP2009004874A0 publication Critical patent/AP2009004874A0/xx
Application granted granted Critical
Publication of AP2479A publication Critical patent/AP2479A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2009004874A 2006-12-06 2007-12-04 Antibacterial quinoline derivatives AP2479A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125499 2006-12-06
PCT/EP2007/063313 WO2008068267A1 (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Publications (2)

Publication Number Publication Date
AP2009004874A0 AP2009004874A0 (en) 2009-06-30
AP2479A true AP2479A (en) 2012-09-27

Family

ID=38126091

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2009004874A AP2479A (en) 2006-12-06 2007-12-04 Antibacterial quinoline derivatives

Country Status (33)

Country Link
US (1) US8415475B2 (hr)
EP (1) EP2099758B1 (hr)
JP (1) JP5466011B2 (hr)
KR (1) KR101490222B1 (hr)
CN (2) CN101553470A (hr)
AP (1) AP2479A (hr)
AR (1) AR064151A1 (hr)
AU (1) AU2007328887B2 (hr)
BR (1) BRPI0720220B8 (hr)
CA (1) CA2669819C (hr)
CL (1) CL2007003514A1 (hr)
CY (1) CY1117766T1 (hr)
DK (1) DK2099758T3 (hr)
EA (1) EA016733B1 (hr)
ES (1) ES2573689T3 (hr)
HK (1) HK1208437A1 (hr)
HR (1) HRP20160585T1 (hr)
HU (1) HUE028769T2 (hr)
IL (1) IL199083A (hr)
JO (1) JO3271B1 (hr)
ME (1) ME02498B (hr)
MX (1) MX2009005978A (hr)
MY (1) MY181645A (hr)
NO (1) NO341983B1 (hr)
NZ (1) NZ576823A (hr)
PL (1) PL2099758T3 (hr)
PT (1) PT2099758E (hr)
RS (1) RS54794B1 (hr)
SI (1) SI2099758T1 (hr)
TW (1) TWI406659B (hr)
UA (1) UA100972C2 (hr)
WO (1) WO2008068267A1 (hr)
ZA (1) ZA200903950B (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
MX355050B (es) 2012-04-27 2018-04-02 Janssen Pharmaceutica Nv Derivados de quinolina antibacterianos.
AU2013331505A1 (en) 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
EP3170810B1 (en) * 2014-07-14 2018-09-19 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
MA41411B1 (fr) * 2015-01-27 2023-07-31 Janssen Pharmaceutica Nv Compositions dispersibles
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
CN105601566A (zh) * 2016-02-02 2016-05-25 张敏 一种护理烧伤后感染的药物组合物
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
WO2018048882A1 (en) 2016-09-06 2018-03-15 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
CN111757879A (zh) * 2018-01-29 2020-10-09 卡地拉健康护理有限公司 用作抗菌剂的杂环化合物
IL302095A (en) * 2020-10-22 2023-06-01 Lunella Biotech Inc Mitochondrial ATP inhibitors targeting the gamma subunit prevent metastasis
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936866A4 (en) 1996-10-28 2001-04-11 Dept Of The Army Us Government COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING ANTIBIOTIC RESIST INFECTIONS
EA011277B1 (ru) * 2004-01-23 2009-02-27 Янссен Фармацевтика Н.В. Производные хинолина и их применение в качестве ингибиторов микобактерий
ATE392423T1 (de) 2004-01-23 2008-05-15 Janssen Pharmaceutica Nv Substituierte chinoline und deren verwendung als inhibitoren von mycobakterien
WO2005075428A1 (en) * 2004-01-29 2005-08-18 Janssen Pharmaceutica N.V. Quinoline derivatives for use as mycobacterial inhibitors
CN101065397B (zh) 2004-09-28 2015-10-21 詹森药业有限公司 一种细菌atp合酶的结合结构域
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011436A1 (en) * 2002-07-25 2004-02-05 Janssen Pharmaceutica N.V. Quinoline derivatives and their use as mycobacterial inhibitors
WO2005117875A1 (en) * 2004-05-28 2005-12-15 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases

Also Published As

Publication number Publication date
US8415475B2 (en) 2013-04-09
CN104744361A (zh) 2015-07-01
JP2010511668A (ja) 2010-04-15
CN104744361B (zh) 2021-06-08
IL199083A0 (en) 2010-03-28
HRP20160585T1 (hr) 2016-06-17
MY181645A (en) 2020-12-30
AR064151A1 (es) 2009-03-18
MX2009005978A (es) 2009-06-16
EA016733B1 (ru) 2012-07-30
JO3271B1 (ar) 2018-09-16
HK1208437A1 (en) 2016-03-04
CA2669819A1 (en) 2008-06-12
SI2099758T1 (sl) 2016-07-29
AP2009004874A0 (en) 2009-06-30
PL2099758T3 (pl) 2016-08-31
UA100972C2 (ru) 2013-02-25
NO341983B1 (no) 2018-03-05
CA2669819C (en) 2016-08-30
RS54794B1 (sr) 2016-10-31
US20100048566A1 (en) 2010-02-25
BRPI0720220B1 (pt) 2020-06-09
AU2007328887A1 (en) 2008-06-12
BRPI0720220B8 (pt) 2021-05-25
PT2099758E (pt) 2016-06-02
HUE028769T2 (en) 2017-01-30
KR101490222B1 (ko) 2015-02-05
EA200970535A1 (ru) 2009-10-30
CY1117766T1 (el) 2017-05-17
AU2007328887B2 (en) 2013-01-17
KR20090086604A (ko) 2009-08-13
DK2099758T3 (en) 2016-06-13
EP2099758A1 (en) 2009-09-16
EP2099758B1 (en) 2016-03-09
TW200838528A (en) 2008-10-01
WO2008068267A1 (en) 2008-06-12
CN101553470A (zh) 2009-10-07
TWI406659B (zh) 2013-09-01
ZA200903950B (en) 2010-08-25
ES2573689T3 (es) 2016-06-09
NZ576823A (en) 2012-01-12
ME02498B (me) 2017-02-20
CL2007003514A1 (es) 2008-07-11
JP5466011B2 (ja) 2014-04-09
NO20092542L (no) 2009-08-25
IL199083A (en) 2014-08-31
BRPI0720220A2 (pt) 2013-12-24

Similar Documents

Publication Publication Date Title
HK1208437A1 (en) Antibacterial quinoline derivatives
IL193265A0 (en) Quinoline derivatives
AP2478A (en) Antibacterial quinoline derivatives
ZA200800783B (en) Antibacterial quinoline derivatives
IL199084A0 (en) Antibacterial quinoline derivatives
IL241548B (en) Antibacterial quinoline derivatives
HK1137428A1 (en) Antibacterial quinoline derivatives
HK1137437A1 (en) Antibacterial quinoline derivatives
ZA200806877B (en) Quinoline Derivatives